Feb 26, 2026 06:31AM
Jan 12, 2026 06:30AM
Dec 17, 2025 09:23AM
Nov 24, 2025 07:33AM
Nov 19, 2025 04:20PM
Nov 18, 2025 04:37AM
Nov 4, 2025 05:13PM Nuvalent to present zidesamtinib trial data at lung cancer conference
Oct 31, 2025 06:03AM
Oct 15, 2025 09:31AM
Oct 13, 2025 12:54PM
Sep 22, 2025 06:34AM
Sep 4, 2025 05:43AM
Aug 19, 2025 06:16AM
Aug 13, 2025 01:08PM Nuvalent to present pivotal zidesamtinib data at lung cancer conference
Aug 7, 2025 06:31AM
Jun 30, 2025 04:06PM
Jun 25, 2025 10:12AM
Jun 25, 2025 06:38AM
Jun 24, 2025 10:24AM
Jun 24, 2025 06:30AM
Apr 29, 2025 01:11PM Nuvalent Inc (NUVL) Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor
Mar 3, 2025 06:45AM
Jan 17, 2025 06:37AM
Jan 13, 2025 06:34AM
Dec 30, 2024 06:32AM
Dec 9, 2024 06:31AM
Nov 13, 2024 07:27AM
Sep 16, 2024 08:57AM TD Cowen Reiterates Buy Rating on Nuvalent (NUVL)
Sep 16, 2024 07:45AM
Sep 13, 2024 09:54AM
Sep 10, 2024 06:33AM
Sep 10, 2024 05:08AM
Sep 9, 2024 11:57AM
Sep 9, 2024 06:31AM
Sep 6, 2024 11:49AM Barclays Reiterates Overweight Rating on Nuvalent (NUVL), PT $100
Aug 30, 2024 07:06AM
Aug 29, 2024 03:42AM
Jul 9, 2024 04:09PM
May 10, 2024 05:47AM
May 9, 2024 06:31AM
Apr 17, 2024 04:32AM
Feb 28, 2024 07:30AM Nuvalent (NUVL) PT Raised to $102 at BMO Capital
Feb 27, 2024 04:22PM
Feb 27, 2024 06:32AM
Feb 27, 2024 06:15AM
Feb 23, 2024 04:11AM
Oct 13, 2023 06:30AM
Sep 5, 2023 06:31AM
Sep 5, 2023 06:30AM Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors
May 11, 2023 06:31AM

64,524 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All